Vitastem Ultra: Helping Hospitals & Nursing Homes Combat HAIs

Infections in healthcare facilities such as hospitals and nursing homes have become a significant issue in the past decade, and even more so, the past several years now. The problem of hospital-acquired infections (HAIs) is prevalent, and it is growing even more so by the day. These infections happen as patients come into contact with bacteria, viruses, and fungi in healthcare facilities, which can lead to severe health risks, complications, and even death.

MRSA and Staphylococcus infections are two of the most common culprits that cause severe HAIs. However, there is hope in the form of Vitastem Ultra – an FDA-registered, patent-pending, new, and incredibly innovative topical antibiotic spray that can help hospitals and nursing homes drastically reduce the risk of HAIs and protect their patients from dangerous infections pretty quickly with more widespread usage of it.

1. What is Vitastem Ultra?

Vitastem Ultra is an innovative topical antibiotic spray that helps treat wounds more effectively and reduce HAIs in healthcare facilities like hospitals, surgery centers, and nursing homes. This unique product contains a potent combination of several natural antibiotics that work together to mainly fight off minor to more severe bacteria like staph & MRSA (flesh-eating bacteria) but has proved to be effective at treating viruses like herpes zoster (shingles), and fungi (finger & toenail fungus). This means that Vitastem Ultra can effectively kill the harmful bacteria that cause MRSA and staph infections – two of the most common pathogens found in healthcare facilities that accelerate HAIs globally.

2. The benefits of using Vitastem Ultra

The use of Vitastem Ultra in hospitals and nursing homes can reduce the risk of HAIs dramatically. By applying their antibiotic spray on the skin, it helps to kill, neutralize, or suppress the growth of harmful bacteria such as MRSA and Staph. Vitastem Ultra helps to promote skin wellness, prevent infections, protect against MRSA, and reduce costly medical visits for patients. It is an essential tool to help fight infections and keep healthcare facilities safe for everyone.

3. How Vitastem Ultra Works

Vitastem Ultra represents a new generation of topical antibiotics that do not destroy the body’s natural gut microbiome, unlike traditional oral antibiotics that can cause more significant issues, including bacterial resistance. This topical antibiotic spray is proven to be extremely effective at penetrating the skin to provide a nurturing environment to rebuild damaged cells, increase blood flow, and provide the necessary nutrients to combat HAI-causing bacteria.

4. Safe to Use for All Age Groups

Vitastem Ultra is entirely safe to use, and its usage is not limited to hospitals and nursing homes; it is available over the counter (OTC) for home use. It is a Class-1 medical product, meaning it’s in the safest of all medical categories. There are no known side effects of using Vitastem Ultra, making it a safe and appropriate treatment for everyone, including people with sensitive skin. It is recommended to apply the product two to three times a day, depending on the severity of the infection.

5. The Future of Vitastem Ultra

Vitastem Ultra is a proven effective solution for combatting the rise of HAIs, as its application reduces the chance of serious medical complications for patients, staff, and visitors. With the ever-increasing concern of rising antibiotic resistance super bugs, the use of Vitastem Ultra is becoming more important every day in helping to combat challenging skin infections. Routine usage in hospitals and nursing homes can help stop the spread of existing infections, reduce healing time, and protect patients from any secondary infections that have been known to prolong hospital stays and even death.

In conclusion, Vitastem Ultra is a very powerful and incredibly innovative topical antibiotic that can help protect patients in healthcare facilities from HAIs with way better wound care treatment options. With the ever-growing concern of antibiotic resistance and the need for infection control, it is clear that Vitastem Ultra is the future of infection protection and control. The product is safe to use, effective, and can readily fit into any infection prevention framework. By using Vitastem Ultra to help combat HAIs, hospitals, and nursing homes can reduce additional infections, prolonged hospital stays, and serious health risks like sepsis and death, creating safer environments for all their patients.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version